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Abstract Invasive fungal infections are frequent and
often deadly complications in patients with malignant
hematological diseases. Voriconazole is a third generation
triazole antifungal with broad activity against most clini-
cally relevant fungal pathogens. Clinical practice often
deviates from insights gained from controlled randomized
trials. We conducted a multi-centre survey to evaluate
efﬁcacy, safety, treatment indications and dosing of vo-
riconazole outside clinical trials. Patients receiving
voriconazole were documented via electronic data captur-
ing. An analysis was conducted after submission of 100
episodes from September 2004 to November 2005. Vo-
riconazole was administered for suspected or proven
invasive fungal infection (IFI) (57%), as empirical
treatment in patients with fever of unknown origin (21%)
and secondary (19%) as well as primary (3%) prophylaxis
of IFI. Investigators’ assessment of fungal infection often
diverted from EORTC/MSG 2002 criteria. A favorable
response was reported in 61.4% for suspected or proven IFI
and 52.4% for empirical treatment. Mortality was 15%,
26.7% of which was attributable to IFI. Breakthrough
fungal infections occurred in four (21.1%) patients with
voriconazole as secondary prophylaxis. Toxicity and
adverse events comprised elevated liver enzymes and
visual disturbances. Although indications frequently devi-
ated from clinical evidence and legal approval,
voriconazole showed efﬁcacy and safety, comparable to
major controlled clinical trials. Data from this survey
demonstrate the difﬁculty of putting drugs to their
approved use in IFI.
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1 Introduction
Patients with malignant hematological diseases receiving
remission-induction chemotherapy are at a high risk of
contracting severe and sometimes lethal invasive fungal
infections, especially invasive pulmonary aspergillosis
(IPA) [1–4].
Voriconazole follows itraconazole as the second tria-
zole-antifungal agent with an enhanced spectrum of
activity against numerous clinically important fungi. This
activity is achieved by inhibition of fungal cytochrome
P450-mediated 14a-lanosterol demethylase, a key enzyme
in ergosterol biosynthesis. Subsequent loss of ergosterol in
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are the primary mode of action of voriconazole.
Among the properties of voriconazole are in vitro
fungistatic activity against most Candida spp., including
those resistant to ﬂuconazole [5–7], fungicidal activity
against several Aspergillus spp. [8–10] as well as pro-
found activity against Fusarium spp. [8–13],
Scedosporium spp. [14], Cryptococcus spp. [7] and other
rare yeasts, molds and dermatophytes, such as Tricho-
sporon spp., Blastomyces spp., Histoplasma capsulatum
and Coccidioides immitis [14, 15]. In a controlled clinical
trial, voriconazole proved superior efﬁcacy and improved
survival when compared with amphotericin B deoxycho-
late in the treatment of invasive aspergillosis [16].
Voriconazole has been approved by the US Food and
Drug Administration (FDA) and European Medicines
Agency (EMEA) for treatment of invasive aspergillosis,
invasive candidiasis in non-neutropenic patients, esopha-
geal candidiasis as well as serious infections caused by
Scedosporium apiospermum and Fusarium spp. in cases
refractory to or intolerant of ﬁrst line treatment [17].
Availability of oral (tablets, suspension) and intravenous
preparations along with a favorable safety proﬁle make
voriconazole a popular drug among clinicians in cases of
suspected or proven invasive fungal infection alike. Vo-
riconazole has become a well-accepted treatment option
in probable and proven IFI [18].
Controlled clinical trials are an imperative tool for
testing drug efﬁcacy and safety in an idealized study
population. To allow comparison between clinical trials,
the European Organisation for Research and Treatment of
Cancer (EORTC) and the Mycoses Study Group (MSG)
have established criteria for the diagnosis of IFIs [21].
These criteria classify IFIs as possible, probable, or proven
according to diagnostic test results. Basically, these criteria
demand major clinical signs in combination with host
factors for a possible diagnosis. For a probable diagnosis,
certain microbiological criteria (e.g. serum galactomannan)
must be fulﬁlled, while a proven diagnosis demands his-
topathological ﬁndings or positive culture from a primary
sterile site. However, trial results do not always translate
into everyday clinical practice. We therefore conducted a
multi-centre survey to evaluate efﬁcacy and safety as well
as common treatment indications and prescribed dosing of
voriconazole outside clinical trials.
2 Methods
Participating investigators were asked to document all
patients receiving voriconazole via online electronic data
capture. Data were collected retrospectively after treatment
completion. Collected data comprised demographic
information, underlying disease, indication for treatment,
earlier antifungal treatment, risk factors for invasive fungal
infection, clinical outcome (including results of diagnostic
imaging, microbiology, lab results, vital signs and sur-
vival), occurrence of adverse events, concurrent
medication, and evaluation of response. Treatment out-
come was evaluated by the investigator. Data were
monitored electronically and manually for plausibility and
completeness and queries were raised to the investigators
in cases that were unclear or incomplete.
An analysis was conducted after submission of 100
episodes. The objective of the analysis was the evaluation
of drug safety and efﬁcacy as well as dosing habits and
indications for voriconazole therapy by means of descrip-
tive analysis. All episodes were registered in the period
from September 2004 to November 2005. Drug toxicities
were evaluated applying common toxicity criteria (CTC)
[19].
3 Results
One-hundred patient courses from the hematological units
of ﬁve different centers (43 from Frankfurt am Main, 42
from Oldenburg, 10 from Cologne, 4 from Frankfurt an der
Oder and 2 from Mainz) were successfully enrolled in the
survey. All relevant data concerning the survey objectives
were present. The most frequent underlying disease was
hematological malignancy (94%). A total of 15 patients
underwent stem cell transplantation, 12 of these were
allogeneic and 8 showed signs of acute or chronic graft-
versus-host disease (GvHD). The ﬁve patients with other
hematological diseases were two patients with aplastic
anemia, two with myelodysplastic syndrome and one with
osteomyeloﬁbrosis. Almost half of the patients (N = 48)
were isolated by means of reverse isolation, 27 patients had
air conditioning with high-efﬁciency particulate air ﬁlters
(HEPA). Only 14 patients were accommodated with no
isolation at all (Table 1).
The most common indication for voriconazole treatment
was suspected or proven IFI by assessment of the investi-
gator (N = 57), 21 patients received voriconazole as
empirical treatment for an episode of fever of unknown
origin (FUO) while considered at risk for an IFI. Other
treatment indications were prophylaxis of IFI (N = 22), 19
of which were considered as secondary prophylaxis after an
earlier episode of IFI. On average, treatment duration was
27 days (Table 1). Fifteen patients died during the obser-
vation period. Causes of death were severe sepsis with
multi-organ failure (N = 6), progression of the underlying
disease (N = 4), progression of IFI (N = 4) and severe
arrhythmia with cardiac arrest (N = 1). The investigator
attributed the lethal arrhythmia to hypokalemia several
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123days after switching antifungal therapy from voriconazole
to liposomal amphotericin B.
For the 57 patients receiving voriconazole for treatment
of suspected or proven IFI, the lung was the most common
site of infection (N = 55). Microbiological evidence was
obtained in two cases of candidemia, one invasive pul-
monary aspergillosis and one Geotrichum capitatum
fungemia. All other patients had suspected invasive pul-
monary aspergillosis by the investigator’s assessment.
Frequent risk factors were exposures to dust due to nearby
construction sites (N = 47), leukopenia (N = 43),
indwelling central venous catheters (N = 39), immuno-
suppressive therapy (N = 35) and mucositis (N = 25). The
initial daily voriconazole dose averaged 6.8 mg/kg. Almost
half of the patients were treated orally from the beginning
(N = 27). In 21 of the remaining 30 patients, therapy was
later switched to oral administration. Treatment success
was rated by the investigators as complete or partial
response in 35 (61.4%) patients. Disease remained stable in
another 11 (19.3%) patients. Progressive disease was
diagnosed in the remaining 11 patients (19.3%). Fifteen
(26.3%) patients were switched to a different antifungal
class (Table 2).
An evaluation of the investigators’ adherence to EO-
RTC/MSG criteria showed a discrepancy between the
softer criteria used in recent clinical trials [16, 20] and the
ofﬁcial 2002 criteria [21]. While recent trials allowed the
Table 1 Patient characteristics at baseline and subsequent vorico-
nazole exposure (N = 100)
Age (years)
a 59 (24–84)
Female 37 (37%)
Mean weight in kg (±SD) 76.2 (±14.7)
Underlying disease
b
Acute myeloid leukemia 72
Acute lymphoblastic leukemia 9
Low grade non-Hodgkin lymphoma 4
Other hematological malignancy 9
Other non-malignant hematological disease 5
Solid tumors 3
Stem cell transplantation 15
Unrelated donor 8
Sibling donor 4
Autologous 3
Graft-versus-host disease 8
Isolation
Reverse isolation 48
HEPA
c 27
No isolation 14
LAF 9
HEPA
c + reverse isolation 2
Treatment indication
Primary prophylaxis 3
Empirical therapy 21
Suspected or proven IFI 57
Secondary prophylaxis 19
Days on voriconazole (±SD) 26.7 (±43.3)
a Median
b Two patients with multiple cancers
c High efﬁciency particulate air ﬁlter
Table 2 Characteristics of patients with suspected or proven IFI by
assessment of the investigator (N = 57)
Site of infection
a
Lung 55 (96.5%)
Blood (fungemia) 2 (3.5%)
Sinus 2 (3.5%)
CNS 1 (1.8%)
Liver 1 (1.8%)
Risk factors
Diabetes mellitus 4 (7%)
HIV 1 (1.8%)
Leukopenia
b 43 (75.4%)
Mucositis 25 (43.9%)
Prior IFI 7 (12.28%)
Central venous catheter 39 (68.4%)
Dust exposure 47 (82.5%)
Surgery 1 (1.8%)
Cytarabine 14 (24.6%)
Purine analogues 7 (12.3%)
Steroids 10 (17.5%)
Other immunosuppressant 4 (7%)
Days with fever (±SD) 7.6 (±6.54)
Total days on antibiotic treatment (±SD) 29.3 (±18.30)
Days on voriconazole (±SD) 26.6 (±26.76)
Average initial voriconazole mg/kg (range) 6.8 (3.125 – 13.559)
Route of administration
Oral only 27 (47.4%)
Switch to oral 21 (36.8%)
Switch to intravenous 4 (7.0%)
Outcome
c
Complete response 19 (33.3%)
Partial response 16 (28.1%)
Stable disease 11 (19.3%)
Progressive disease 11 (19.3%)
Switch to other antifungal 15 (26.3%)
Liposomal amphotericin B 8 (14.0%)
Caspofungin 5 (8.8%)
Other 2 (3.5%)
a Super additive because of patients with multiple infection sites
b As deﬁned as less than 1,000 leukocytes/ll
c As assessed by investigator
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123investigator to rate evidence as probable without microbi-
ological ﬁndings, the ofﬁcial criteria demand at least one
microbiological criterion. Thus, 35 of the 57 cases with
suspected or proven IFI had probable IFI according to the
softer criteria, but only four patients had probable IFI when
applying the ofﬁcial EORTC/MSG criteria. Independent of
the applied edition of the EORTC/MSG criteria, 19 patients
did not meet the requirements for classiﬁcation of evidence
even as possible (Table 3).
In the 21 patients, where voriconazole was given as
empirical therapy, oral administration was preferred
(N = 16). Average duration of fever was higher than in
those with suspected or proven IFI, averaging 11.6 days.
Treatment duration averaged 9.7 days, markedly shorter
than the other subgroups. Eleven patients improved under
empirical treatment, six were stable while four showed
signs of progressive infection. There was a frequent switch
of therapy to antifungals of different classes, i.e. liposomal
amphotericin B (N = 3), caspofungin (N = 4) or their
combination (N = 1) (Table 4).
Almost all patients on voriconazole as secondary pro-
phylaxis (N = 19) received their treatment orally
(N = 18). Mean treatment duration was 48.8 days. Four
breakthrough IFIs were reported. Therapy was switched to
other antifungals in seven cases, most often to caspofungin
(N = 5) (Table 5).
The most frequent adverse events at least possibly
related to voriconazole treatment by the investigators
were visual disturbances (N = 6), nausea (N = 3) and
rash (N = 3) (Table 6). At least one liver function test
showed grade 3–4 toxicity, applying the common toxicity
criteria in 15 cases, seven of which were attributed to
voriconazole by the investigators. In this survey, gamma
glutamyl transpeptidase was the most sensitive marker for
voriconazole toxicity, showing a marked elevation in 12
cases of investigator attributed toxicity. However, no
deﬁnite preference could be detected for any of the liver
parameters assessed. None of the four patients with grade
3–4 nephrotoxicity were attributed to voriconazole
(Table 6).
4 Discussion
In our survey, voriconazole was efﬁcacious in 61.4% of
patients treated for suspected or proven IFI (by assessment
of the investigator). Favorable response was documented
for 52.4% of patients receiving voriconazole as empirical
therapy. This observation is comparable to prior results.
For the treatment of suspected or proven IFI, especially
IPA, investigator assessed favorable results deﬁned as
complete or partial responses were obtained in 61.4% as
compared to 52.8% in Herbrecht’s trial [16]. In the
Table 3 Evidence rating for patients with IFI suspected or proven by
the investigator (N = 57)
Investigator
assessment
According to
criteria from
recent clinical
trials [16, 20]
According
to EORTC/
MSG 2002 [21]
Proven 3/57 (5.3) 2/57 (3.5) 2/57 (3.5)
Probable 26/57 (45.6) 35/57 (61.4) 4/57 (7.0)
Possible 14/57 (24.6) 1/57 (1.8) 32/57 (56.1)
Not deﬁned 14/57 (24.6) 19/57 (33.3) 19/57 (33.3)
Values in parenthesis are in percentage
Table 4 Voriconazole dosing and treatment outcome
Empirical
treatment
(N = 21)
Secondary
prophylaxis
(N = 19)
Average initial
voriconazole dose in
mg/kg (range)
5.7 (2.469–10.870) 5.7 (3.3–7.5)
Route of administration
Oral only 16 (76.2%) 18 (94.7%)
Switch to oral 2 (9.5%) 0
Switch to intravenous – 1 (5.3%)
Days with fever (±SD) 11.6 (±11.17) n. a.
Days on antibiotic
treatment (±SD)
29.8 (±13.55) n. a.
Days on voriconazole
(±SD)
9.7 (±6.94) 48.8 (±84.31)
Breakthrough IFI n. a. 4 (21.1%)
Outcome
a
Progressive disease 4 (19.1%) n. a.
Stable disease 6 (28.6%) n. a.
Partial response 1 (4.8%) n. a.
Complete response 10 (47.6%) n. a.
Switch to other antifungal 8 (38.1%) 7 (36.8%)
Liposomal amphotericin B 3 (14.3%) 2 (10.1%)
Caspofungin 4 (19.1%) 5 (26.3%)
Liposomal amphotericin
B + caspofungin
1 (4.8%) 0
Table 5 Other adverse events (N = 100)
Visual disturbance 6
Nausea 3
Rash 3
Hallucination 2
Vomiting 2
Diarrhea 1
Drug fever 1
Edema 1
Adverse events at least possibly related to voriconazole by judgment
of the investigator
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123empirical setting, favorable response was reported in
52.4%, while only a 26% overall response was reported
previously [22]. However, the outcome evaluation was
supposedly far more rigid in the clinical trials than the self-
assessment of the registry contributors.
When compared to earlier prospective controlled clini-
cal trials [16, 22], adverse events were less common.
Visual disturbances were only reported in 6% and hallu-
cinations in 2% as compared to 44.8 and 6.6%,
respectively, in aspergillosis [16] and to 21.9 and 4.3%,
respectively, in febrile neutropenia [22]. However, adverse
event reporting is naturally less stringent in a survey than in
controlled clinical trials.
Analysis of survey data did not reveal yet unknown
toxicities of voriconazole. Treatment-related grade 3 or 4
hepatotoxicity was observed in 15 patients. Further fre-
quent adverse events were visual disturbances (6%), rash
(3%) and nausea (3%).
Signiﬁcant elevations of serum alkaline-phosphatase
activities ([39 baseline value) occurred in 2.9% compared
to 2.3% of grade 3–4 CTC toxicity in our study, aspartate
aminotransferase ([39 baseline value) in 8.9 versus 4.4%,
alanine aminotransferase ([39 baseline value) in 7.2 ver-
sus 2% and bilirubin (C1.59 baseline value) in 27.2 versus
6.6% [22].
Our survey demonstrates that clinical reality regularly
strays from approved indications and evidence based
choice of treatment. A total of 43% of the reported patients
received voriconazole prophylactically or empirically. One
third of the 57 patients with voriconazole for treatment of
actual IFI lacked sufﬁcient evidence of IFI according to
EORTC/MSG criteria [21]. Thus, a rate of as much as 62%
may be considered as off-label use. Furthermore, all ran-
domized controlled clinical trials on voriconazole used the
intravenous formulation as initial treatment. Despite this,
39.5% of patients with at least possible IFI were started on
oral voriconazole. Looking at these ﬁgures, one could
claim that only 23% of the patients reported were treated as
approved by the German health administration and
according to best scientiﬁc evidence. But does this mean
patients were not treated in their best interest?
The difﬁculty of proving IFI remains a dilemma in
choosing adequate treatment. There is still no sensitive and
speciﬁc non-invasive method for detection of invasive
pulmonary aspergillosis (IPA) [21, 23–25]. Controlled
clinical trials on antifungal agents normally use the current
EORTC/MSG criteria with or without modiﬁcations, while
the consensus committee clearly discourages from clinical
decision-making based on their guideline [21]. Addition-
ally, especially in palliative situations, long-term inpatient
treatment with intravenous antifungals is often undesirable.
Finally, no antifungal has yet been approved for secondary
prophylaxis of IPA.
In the above clinical situations, voriconazole offers a
ﬂexible and tolerable treatment option. Still, the many
difﬁculties in the diagnosis and treatment of invasive fun-
gal infections should not be used as a carte blanche in
clinical decision making. Physicians should strive towards
establishing the most accurate diagnosis possible and then
treat according to current evidence.
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Table 6 Highest grade of
treatment-emergent renal and
hepatic adverse events
Values given in parenthesis are
in percentage
a Toxicity judged at least
possibly attributable to
voriconazole treatment by the
investigator
CTC-toxicity [19] Grade-1 (%) Grade-2 (%) Grade-3 (%) Grade-4 (%) N evaluable
Liver
GOT (AST) 29 (31.5) 5 (5.4) 2 (2.2) 2 (2.2) 92
6 (6.5)
a 1 (1.1)
a 1 (1.1)
a 1 (1.1)
a
GPT (ALT) 20 (20.2) 4 (4) 1 (1) 1 (1) 99
3 (3)
a 3 (3)
a 0 (0)
a 1 (1)
a
GGT 14 (15.7) 14 (15.7) 11 (12.4) 0 (0) 89
3 (3.4)
a 4 (4.5)
a 5 (5.6)
a 0 (0)
a
AP 17 (19.5) 4 (4.6) 2 (2.3) 0 (0) 87
7 (8)
a 1 (1.2)
a 1 (1.2)
a 0 (0)
a
Bilirubin 10 (11) 5 (5.5) 4 (4.4) 2 (2.2) 91
3 (3.3)
a 3 (3.3)
a 3 (3.3)
a 1 (1.1)
a
Kidney
Creatinine 11 (11) 6 (6) 2 (2) 2 (2) 100
2 (2)
a 1 (1)
a 0 (0)
a 0 (0)
a
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